Search research articles
Contact Us
Filters
Showing results (121-130 of 170) with videos related to
Page
of 17
Sort By:
Hemasphere
|
December 10, 2025
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy
Lukas Scheller, Xiang Zhou, Henry Loeffler-Wirth, et al.
Hemasphere
|
July 12, 2024
Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma
Larissa Haertle, Umair Munawar, Hipólito N C Hernández, et al.
Haematologica
|
January 8, 2026
Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma
Seungbin Han, Umair Munawar, Marietta Truger, et al.
Cancer Medicine
|
October 2, 2025
Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
Niels W C J van de Donk, Ajai Chari, Thomas Martin, et al.
British Journal of Haematology
|
September 30, 2016
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study
Artur Jurczyszyn, Hareth Nahi, Irit Avivi, et al.
British Journal of Haematology
|
May 8, 2024
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study
Xiang Zhou, Vivien Wagner, Lukas Scheller, et al.
Blood
|
May 23, 2018
The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma
Leo Rasche, Edgardo J Angtuaco, Terri L Alpe, et al.
Haematologica
|
September 28, 2019
IKZF1/3 and CRL4<sup>CRBN</sup> E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma
Santiago Barrio, Umair Munawar, Yuan Xiao Zhu, et al.
Clinical Epigenetics
|
April 2, 2026
Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma
Seungbin Han, Larissa Haertle, Umair Munawar, et al.
Blood Cancer Discovery
|
February 13, 2026
Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapy
Jan H Frenking, Christine Riedhammer, Thomas Hielscher, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 170) with videos related to
Sort By:
Page
of 17
Hemasphere
|
December 10, 2025
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy
Lukas Scheller, Xiang Zhou, Henry Loeffler-Wirth, et al.
Hemasphere
|
July 12, 2024
Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma
Larissa Haertle, Umair Munawar, Hipólito N C Hernández, et al.
Haematologica
|
January 8, 2026
Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma
Seungbin Han, Umair Munawar, Marietta Truger, et al.
Cancer Medicine
|
October 2, 2025
Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
Niels W C J van de Donk, Ajai Chari, Thomas Martin, et al.
British Journal of Haematology
|
September 30, 2016
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study
Artur Jurczyszyn, Hareth Nahi, Irit Avivi, et al.
British Journal of Haematology
|
May 8, 2024
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study
Xiang Zhou, Vivien Wagner, Lukas Scheller, et al.
Blood
|
May 23, 2018
The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma
Leo Rasche, Edgardo J Angtuaco, Terri L Alpe, et al.
Haematologica
|
September 28, 2019
IKZF1/3 and CRL4<sup>CRBN</sup> E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma
Santiago Barrio, Umair Munawar, Yuan Xiao Zhu, et al.
Clinical Epigenetics
|
April 2, 2026
Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma
Seungbin Han, Larissa Haertle, Umair Munawar, et al.
Blood Cancer Discovery
|
February 13, 2026
Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapy
Jan H Frenking, Christine Riedhammer, Thomas Hielscher, et al.
Page
of 17